Strategies for the safe use of colistin

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 10, 2015, Pages 1237-1247

  Ortwine, Jessica K ^a,b   Sutton, Jesse D ^c,d   Kaye, Keith S ^e,f   Pogue, Jason M ^f,g  

^a PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Baptist Health Louisville ^*  (United States)

^d University of Louisville School of Medicine   (United States)

^e DETROIT MEDICAL CENTER   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g SINAI GRACE HOSPITAL   (United States)

Author keywords

carbapenem resistance; colistimethate; colistin; nephrotoxicity; pharmacokinetics; polymyxin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ASCORBIC ACID; BETA LACTAM ANTIBIOTIC; CALCINEURIN INHIBITOR; CARBAPENEM DERIVATIVE; COLISTIMETHATE; COLISTIN; CONTRAST MEDIUM; CREATININE; HYPERTENSIVE AGENT; IMIPENEM; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SERUM ALBUMIN; SULTAMICILLIN; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; COMORBIDITY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HUMAN; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OBESITY; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT DURATION; URINARY EXCRETION; VENTILATOR ASSOCIATED PNEUMONIA; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG RESISTANCE; GRAM NEGATIVE BACTERIUM; KIDNEY DISEASE;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DRUG RESISTANCE; GRAM-NEGATIVE BACTERIA; HUMANS; KIDNEY DISEASES;

EID: 84941741152     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1070097     Document Type: Review

References (71)

1. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006;10(1):R27
2. Nation RL, Li J, Cars O, et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 2015;15(2):225-34
3. Boucher HW,Talbot GH,Bradley JS,et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America Clin Infect Dis 2009 48 1)1-12
4. Boucher HW, Talbot GH, Benjamin DK, et al. 10 x '20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56(12):1685-94
5. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40(9):1333-41
6. Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005;25(1):11-25
7. Li J, Nation RL, Turnidge JD, et al. Colist in: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6(9): 589-601
8. Gauthier TP, Lantz E, Frederick C, et al. Variability within investigations of intravenous colistin: the scope of the problem. Clin Infect Dis 2014;58(9):1340-2
9. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012;18(1):18-29
10. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resista nt Acinetobacter baumannii ventilator-Associated pneumonia. J Infect 2008;56(6):432-6
11. Durakovic N, Radojcic V, Boban A, et al. Efficacy and safety of colistin in the treatment of infections c aused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med 2011; 50(9):1009-13
12. Gounden R, Bamford C, van Zyl-Smit R, et al. S afety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 2009;9:26
13. Lim SK, Lee SO, Choi SH, et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci 2011;26(3):325-31
14. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010;65(5): 1019-27
15. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imip enem in the treatment of ventilator-Associated pneumonia: a matched case-control study. Intensive Care Med 2007;33(7):1162-7
16. Hachem RY, Chemaly RF, Ahmar CA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007;51(6) : 1905-11
17. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007;11(5):402-6
18. Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in acinetobacter and pseudomonas infections: a prospective cohort study. Intensive Care Med 2005;31(8):1058-65
19. Rocco M, Montini L, Alessandri E, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 2013;17(4):R174
20. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colisti n therapy for microbiologically documented multidrug-resistant Gramnegative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;35(2):194-9
21. Deryke CA, Crawfor d AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010;54(10):4503-5
22. Kalin G, Alp E, Coskun R, et al. Use o f high-dose IV and aerosolized colistin for the treatment of multidrug-resistant acinetobacter baumannii ventilator-Associated pneumonia: do we really need this treatment? J Infect Chemother 2012;18(6):872-7
23. SorlíL, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 2013;13:380
24. Garonzi k SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agent s Chemother 2011;55(7):3284-94
25. Pogue JM,Lee J,Marchaim D,et al. Incidence of and risk factors for colistin-Associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011 53(9) 879-84
26. Bailey TC, Little JR, Littenberg B, et al. A meta-Analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24(5):7 86-95
27. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-Analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013;57(2):734-44
28. Balkan II, Dogan M, Durdu B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014;46(10):678-85
29. Collins JM, Haynes K, Gallagher JC. Emergent renal dysfunction with colistin pharmacotherapy. Pharmacotherapy 2013; 33(8):812-16
30. Gauthier TP, Wolowich WR, Reddy A, et al. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012;56(5): 2392-6
31. Pogue JM, Kaye KS. Nephrotoxicity associated with colistin therapy: a comparative analysis of older and younger adults. Abstract P2118 presented at: 23rd European Congress of Clinical Microbiology and Infectious Diseases; 27-30 April 2013; Berlin, Germany
32. Rigatto MH, Behle TF, Falci DR, et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospectiv e cohort study. J Antimicrob Chemother 2015;70(5):1552-7
33. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 2009;34(5):434-8
34. Kwon JA, Lee JE, Huh W, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010;35(5):473-7
35. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012;54(12 ):1720-6
36. Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 2011;31(12):1257-64
37. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-Associated nephrotoxicity. J Infect 2011;62(2):187-90
38. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 2013;56(3): 398-404
39. Forrest A, Silveira FP, Thamlikitkul V, et al. Toxicodynamics (T D) for colistin-Associated changes in creatinine clearance (CrCl). Abstract A-038a presented at: 54th Interscience Conference of Antimicrobial Agents and Chemotherapy; 5-9 Sept 2014; Washington D.C
40. Falagas ME, Fragouli s KN, Kasiakou SK, et al. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005;26(6):504-7
41. Hartzell JD, Neff R, Ake J, et al. Nephr otoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009;48(12):1724-8
42. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28(5):1008-11
43. Boisson M, Jacobs M, Gregoire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother 201 4;58(12):7331-9
44. Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Che st 2010;138(6):1333-9
45. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gr am-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008;30(1):143-51
46. He H,Li JC,Nation RL,et al. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats J Antimicrob Chemother 2013 68 10)2311-17
47. Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010;54(3): 1117-24
48. Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010;65(9): 1984-90
49. Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56(8):4241-9
50. Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-Associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 201 2;54(5): 670-80
51. Polymyxin E. Colistin. In: Chambers HF, Eliopoulos GM, Gilbert DN, Saag MS editors. The Sanford Guide to Antimicrobial Therapy. 45th edition. Antimicrobial Therapy, Inc; Sperryville, VA: 2015
52. Ni W, Shao X, Di X, et al. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-Analysis. Int J Antimicrob Agents 2015;45(1):8-18
53. Zusman O, Avni T, Leibovici L, et al. Systematic review and meta-Analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 2013;57(10):5104-11
54. Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007;45(6): 753-60
55. Wallace SJ, Li J, Nation RL, et al. Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob Agents Chemother 2008;52(3):1159-61
56. Bergen PJ, Li J, Nation RL, et al. Comparison of once-, twice-And thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic m odel. J Antimicrob Chemother 2008; 61(3):636-42
57. Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003;52(6):987-92
58. Abdelraouf K, Braggs KH, Yin T, et al. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 2012;56(9):4625-9
59. Abd elraouf K, Chang KT, Yin T, et al. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother 2014;58(7): 4200-2
60. Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 2015;35(1):28-33
61. Kunin CM, Bugg A. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J Infect Dis 1971;124(4):394-400
62. W S Yapa S, Li J, Patel K, et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalationa l administration. Antimicrob Agents Chemother 2014;58(5):2570-9
63. Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-Associated pneumonia: a systematic rev iew and metaanalysis. Crit Care Med 2015;43(3):527-33
64. Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for s election of dosage regimens. Clin Infect Dis 2013;57(4): 524-31
65. Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated w ith colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 2014;58(5):2740-6
66. Tuon FF, Rigatto MH, Lopes CK, et al. Risk factors for acute kidney injury in patients treated with po lymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 2014;43(4):349-52
67. Nation RL,Velkov T,Li J Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 2014 59 1)88-94
68. Petrosillo N, Giannella M, Antonelli M, et al. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Age nts Chemother 2014;58(2):851-8
69. Yousef JM, Chen G, Hill PA, et al. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011;55(9):4044-9
70. Yousef JM, Chen G, Hill PA, et al. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 2012;67(2):452-9
71. Sirijatuphat R, Limmahakhun S, Sirivatanauksorn V, et al. Effect of ascorbic acid on colistin-Associated nephrotoxicity: A preliminary clinical study. Antimicrob Agents Chemother 2015;59(6):3224-32